THEY BELIEVE IN US
Since its inception in 2014, the company has been developping physiological models, particularly in partnership with the world’s leading pharmaceutical and cosmetic groups.
In 2015 we signed a research and development agreement on our 3D bioprinting technology for advanced skin care applications. Our combined expertise aim at enhancing bioprinted 3D tissue models to support the development and testing of cosmetic bioactives for skin care applications.
In 2017, two years after concluding an agreement on research and development in cosmetics, we signed a framework agreement on further development and services in the field of 3D bioprinting technology. The main goal was to further improve the 3D laser-assisted bioprinted skin models that have been co-developed since 2015 to evaluate cosmetic ingredients for skin care applications.
There is convincing evidence, in animal models and in humans, that deep osteochondral defects of the joint surface lead to a high rate of osteoarthritis (OA) over time.
the way for high-volume, affordable production of entire biological
joints, addressing a major socioeconomic challenge of the European ageing society.
Taken together we strive to develop an automated, GMP-grade platform producing large, patterned and vascularised joint implants providing also a paradigm shift for generic automated manufacturing of organoid-based tissue implants.
Poietis is member of the EU H2020 FET-Open Pan3DP, a multidisciplinary project that brings together experts in developmental biology, computational biology, organ modeling and tissue engineering, from both academia and industry.
We will biomimic developmental processes to fabricate 3D bioprinted pancreatic tissue units that allow sustained cell viability, expansion and functional differentiation ex vivo.
H2020 Consortium ASCTN : : « Training on Advanced Stem Cell Technologies in Neurology »
Poietis is member of the H2020 Consortium ASCTN : « Training on Advanced Stem Cell Technologies in Neurology »
ASCTN-Training is addressing existing gaps within Human Stem Cell-based Neuronal disorders (NDs) Modelling (NDM) for research to develop new medicines for the treatment of neurological disorders (e.g. Parkinson´s (PD), Huntington´s (HD) and Demyelination’s (DM) diseases), which occur as a result of acute or progressive loss of cells, glial or neuronal, and structures and function in the brain.
Poietis is the leader of a European project of the EUREKA-EUROSTARS programme which has just been positively evaluated by a panel of independent experts. This project, MIR-LAB, has the German Fraunhofer Institute for Laser Technology as partners as well as three other SMEs: APE and Canlas in Germany and Innoflence in Spain. This is a 3-year cooperative project aimed at developing new optical components for bio-imprinting (total budget of €1.15M co-financed at over 60%).
The EUROSTARS programme supports innovative SMEs involved in European collaborative projects and targets companies with high R&D investments as a priority. Its total budget is €1.14 billion.
RESTORE H2020-FET Flagship program on Advanced Therapies
This huge European project, that will help to turn the promise of Advanced Therapies (cell therapy, gene therapy, and tissue engineering) into reality, is entering the preparatory phase to become a Large-Scale Research Initiative.